Objetivo Mapear os cuidados em saúde do dispositivo Pegfilgrastim on-body injector na
prevenção de neutropenia em adultos com câncer em assistência domiciliar após …

Results: A total of 10 articles were included, whose results were subdivided into categories:
patient compliance, health team opinion, patient workload in cancer treatment and device …

Introduction Granulocyte colony-stimulating factors are used in medical oncology for the
prevention of neutropenia. On-body injectors (OBI) have an advantage over the traditional …

Purpose The on-body injector (OBI) automatically delivers pegfilgrastim the day after
chemotherapy (CTx), thus eliminating the need of return visits to the medical office for …

Purpose We evaluated the incidence of febrile neutropenia (FN) and related clinical
outcomes among patients treated with myelosuppressive chemotherapy for nonmyeloid …

Background Febrile neutropenia associated with some chemotherapy regimens can lead to
potentially fatal complications and high health care costs. Administration of pegfilgrastim …

Introduction Myelosuppression, a challenge in cancer treatment, often results in severe
complications. Prophylactic granulocyte colony-stimulating factors, particularly pegfilgrastim …

e18859 Background: Pegfilgrastim prophylaxis reduces risk of febrile neutropenia (FN) and
administration is recommended at least 24 h after cytotoxic chemotherapy. The pegfilgrastim …

Objectives Febrile neutropenia (FN) is a serious side effect of strong chemotherapy.
Pegfilgrastim prophylaxis reduces the incidence of FN and should be administered at least …

Background Breast cancer chemotherapy often carries a high risk of febrile neutropenia
(FN); guidelines recommend prophylaxis with granulocyte colony-stimulating factor (G-CSF) …